Non-erythropoietic EPO-derived peptide
ARA-290
Cibinetide
InvestigationalAn investigational peptide derived from a tissue-protective region of erythropoietin and studied in inflammatory and neuropathy-related settings.
FULL RESEARCH GRAPHIC
ARA-290 research overview
A dedicated Cybertide visual covering the tissue-protective signaling concept and the investigational status of ARA-290, also known as cibinetide.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
InvestigationalSmall clinical studies can identify signals worth testing but do not establish approval, long-term safety, or broad regenerative effects.
BOUNDARY CHECK
CONTEXT REQUIREDEarly signals from small studies require confirmation in larger, controlled research before broad safety or benefit claims can be made.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
No submitted laboratory document is currently connected to this compound page. That is missing evidence—not a failed test.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
10 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
3.0 mL BAC-water workflow
- First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
- Clean both vial stoppers with alcohol and allow them to dry.
- Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
- Gently roll or swirl until dissolved; do not shake.
- Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
Phase 2 study: 4 mg daily for 28 days
One phase 2 study used 4 mg ARA-290 subcutaneously once daily for 28 days. Another pilot used 2 mg intravenously three times weekly for four weeks. These were investigational study regimens, not approved guidelines.
Primary study — ARA-290 in type 2 diabetes ↗U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.